T cells have a pivotal protective role in defense against infection and cancer but also are instrumental in the development of many autoimmune diseases. The regulation of nutrient uptake and utilization in T cells is critically important for the control of their differentiation, and manipulating metabolic pathways in these cells can alter their function and longevity. While the importance of T cell metabolic remodeling in different physiological settings is not fully understood, there is a growing realization that inappropriate metabolic remodeling underlies many aberrant immune responses and that manipulating cellular metabolism can beneficially enhance or temper immunity. Here we comment on the basic metabolic pathways in T cells, followed by a discussion on up-to-date findings about the relationship between metabolism and T cell function and longevity. Furthermore, we expand on potential approaches and applications in which T cells might be manipulated by the reprogramming of metabolic pathways for therapeutic purposes.
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T cells have a pivotal protective role in defense against infection and cancer but also are instrumental in the development of many autoimmune diseases. The regulation of nutrient uptake and utilization in T cells is critically important for the control of their differentiation, and manipulating metabolic pathways in these cells can alter their function and longevity. While the importance of T cell metabolic remodeling in different physiological settings is not fully understood, there is a growing realization that inappropriate metabolic remodeling underlies many aberrant immune responses and that manipulating cellular metabolism can beneficially enhance or temper immunity. Here we comment on the basic metabolic pathways in T cells, followed by a discussion on up-to-date findings about the relationship between metabolism and T cell function and longevity. Furthermore, we expand on potential approaches and applications in which T cells might be manipulated by the reprogramming of metabolic pathways for therapeutic purposes.
During the course of an immune response, naive T cells recognize antigen in the context of major histocompatibility complex molecules and, with proper co-stimulation, become activated, rapidly proliferate and produce a variety of effector molecules, which leads to the control of a pathogen or tumor. The activation, clonal expansion and acquisition of effector functions of T cells are energetically demanding processes that are tightly coupled changes in cellular metabolism. Accessing nutrients and meeting metabolic demands are necessary for T cells to survive, proliferate and properly perform their functions 1, 2 . Although there is an ever-growing appreciation of how cellular metabolism supports many aspects of T cell biology and that many metabolic pathways might be amenable to manipulation, reliably targeting T cell metabolism for disease treatment is still in its early stages. In this Perspective, we discuss the current understanding of T cell function and longevity regulated by metabolism and comment on potential strategies and approaches for integrating metabolism into immunotherapy design.
Metabolism in a nutshell
ATP transports chemical energy within cells and is generated by two main processes: glycolysis and oxidative phosphorylation (OXPHOS). Depending on the needs of a cell, metabolism can be weighted toward either anabolic reactions (the construction of molecules required for growth and biosynthesis) or catabolic reactions (the breakdown of macromolecules into smaller units for energy production or use in anabolic pathways) 1, 2 . A balance of these processes allows cells to maintain energy homeostasis (Fig. 1) . Glucose is one of the main nutrients from which cells extract energy. The glycolytic pathway converts glucose into pyruvate via a series of intermediate metabolites that can enter other pathways (such as the pentose phosphate pathway) and contribute to biosynthesis and cell growth. Glucose-derived pyruvate can be converted in the mitochondria into acetyl-CoA, which enters the tricarboxylic acid (TCA) cycle, or it can be converted in the cytoplasm into lactate, which is excreted from the cell. In addition to the generation of ATP and biosynthetic precursors, glycolysis also helps to maintain the NAD + -NADH redox balance, which reflects the metabolic health of a cell. Other major substrates that are used by T cells include amino acids such as glutamine, which is metabolized via glutaminolysis, and lipids, which are 'burned' via fatty acid oxidation (FAO). The intermediates produced by these processes also enter the TCA cycle. The coenzymes NADH and FADH 2 are generated by the oxidation of substrates in the TCA cycle and donate electrons to the electron-transport chain for OXPHOS (Fig. 1) . OXPHOS is highly efficient and is able to yield over ten times more ATP per molecule of glucose than is produced by glycolysis alone. In addition to generating reducing equivalents for OXPHOS, the TCA cycle provides substrates for biosynthesis, such as citrate, which can be exported to the cytosol for fatty acid synthesis (FAS) (Fig. 1) . A cell must balance its nutrient utilization and metabolism to meet demands for energy, biosynthesis and redox balance.
Adjusting metabolism to T cell function Circulating naive T cells are quiescent, have low metabolic demands and use predominantly OXPHOS to generate ATP. Upon T cell antigen receptor (TCR)-mediated recognition of antigens and costimulatory signals, T cells become activated and adopt an anabolic metabolism. Nutrients are no longer used solely for survival and homeostasis but are also used for the generation of building blocks for clonal expansion and for effector functions, such as the secretion of cytokines and cytolytic molecules important for clearing tumors and pathogens. After a tumor or an infection is cleared, the vast majority of antigen-specific effector T cells die and a small subset of long-lived memory T cells persist that cancer antigen, nutrient depletion, as a distinct mechanism, can dampen T cell effector function. In addition, in a glucose-limiting microenvironment, insufficient phosphoenolpyruvate, a metabolite in the glycolytic pathway, promotes calcium re-uptake to the sarco-endoplasmic reticulum in T cells, and this leads to dampened anti-tumor T cell function 17 . T cells with genetically increased production of phosphoenolpyruvate have enhanced effector functions and restrict tumor growth in mice. Together these data suggest that substrate concentrations in a local microenvironment can have a marked impact on immune-cell function and that altering tumor and/or T cell metabolism can effectively change nutrient availability and permit T cells to function more effectively in a particular niche.
The kinase AMPK is an important metabolic sensor in T cells that monitors and reacts to changes in the AMP/ATP ratio. To dampen anabolism and increase energy during metabolic stress, AMPK inhibits mTOR activity through several pathways. AMPK phosphorylates the tumor suppressor TSC2, which converts the GTP-binding protein Rheb into its inactive form and dampens mTOR activity. AMPK also phosphorylates the regulatory and mTOR-binding protein Raptor, which leads to inhibition of mTOR 3 . Accordingly, AMPKa-deficient CD8 + T cells have higher glycolytic activity in vitro than that of their AMPKa-sufficient counterparts 15 . AMPK has been shown to contribute to energy plasticity by promoting oxidative metabolism during metabolic stress due to low glucose conditions and thus is needed for durable effector T cell responses in vivo 18 . However, AMPK is dispensable for the proliferation and effector function of CD8 + T cells in vivo 19 . These contrasting findings probably reflect the fact that even subtle differences in the nutrient conditions, mTOR activity and activation state of cells can have profound effects on the role of AMPK in metabolic adaptations in T cells in vivo.
T cells not only rely on glucose but also depend on amino acids for survival and function. Depletion of glutamine in the culture medium blocks the proliferation and cytokine production of T cells 20 , and it is likely that competition for glutamine in the tumor microenvironment provide long-term protective immunity. Unlike effector T cells, memory T cells do not rapidly proliferate and thus do not require high rates of anabolic metabolism. Instead, they generate energy to support selfrenewal 1,2 . During each phase of a T cell's life, metabolism is 'tuned' to match the T cell's function and fate.
Signals from the TCR, costimulatory molecules and growth-factor cytokines lead to the activation of signaling pathways that promote transcriptional programs important for effector functions. These signals also lead to activation of the kinase mTOR, which mediates the induction of glycolysis via multiple pathways to support cell growth, proliferation and function 3 . The activation of mTOR induces expression of the glucose transporter Glut1 (ref. 4) , and transgenic expression of Glut1 enhances T cell proliferation and cytokine production 5 . Increased glycolysis and glucose uptake is associated with the augmented effector functions that occur after T cell activation 6 . In addition, the bi-functional metabolic enzyme and RNA-binding protein GAPDH post-transcriptionally regulates optimal production of interferon-g in T cells via the glycolytic pathway 7 . When cells engage in glycolysis to a high degree, GAPDH is occupied by its metabolic function. When T cells are unable to use glycolysis, GAPDH becomes disengaged from its metabolic function and binds to mRNA encoding interferon-g and prevents its efficient translation. These data demonstrate that in addition to providing fuel and biosynthetic precursors, metabolic pathways are able to modulate immune cell effector function by directly influencing the translation of specific mRNAs.
Activation of mTOR and engagement of glycolysis lead to the expression of downstream transcriptional regulators, such as HIF-1a, c-Myc and ERRa. These factors regulate metabolism in T cells and activate pathways involved in rapid cell proliferation and effector function 8 . The HIF-1a-dependent transcriptional program mediates glycolysis in T cells and favors development of the T H 17 subset of helper T cells while dampening regulatory T cells 9 . Activation of c-Myc induces the expression of enzymes involved in glycolysis and glutaminolysis, the products of which contribute to the synthesis of lipids, amino acids and nucleic acids for cellular expansion 10 . ERRa promotes the expression of genes encoding factors involved in mitochondrial biogenesis, fatty acid metabolism and OXPHOS in metabolic tissues, such as muscle and adipose tissue 11 . ERRa is also an important metabolic regulator of the homeostasis and function of effector CD4 + T cells, broadly affecting metabolic gene expression and glucose metabolism 12 . In addition, the transcription factor IRF4 controls the differentiation and function of effector T cells 13, 14 . IRF4 regulates the expression of key molecules required for glycolysis and 'translates' TCR affinity into the appropriate transcriptional programs that link metabolic function with clonal selection and effector differentiation in T cells 13, 14 . Overall, a broad spectrum of signaling pathways and transcriptional target genes are involved in metabolism and metabolic transitions that affect T cell function.
The availability of nutrients also greatly influences T cells. T cells rely on glucose for their cytolytic activity and cytokine production, and in glucose-limiting conditions, these functions are impaired 6, 7, 15 . In an extension of that idea, diminished availability of glucose within the tumor microenvironment dampens anti-tumor responses 16, 17 . CD8 + T cells isolated from antigenic tumors with genetically enhanced rates of glycolysis have decreased interferon-g expression and activation of mTOR targets compared with that of T cells in control transduced tumors with basal levels of glycolysis. The impaired function of T cells in this setting is attributed to low concentrations of extracellular glucose in the tumor milieu 16 . Control tumors and the tumors with enhanced glycolysis express the same main tumor-rejection antigen, which illustrates that even in situations in which the immune system can recognize To support the unique metabolic phenotype noted above, memory T cells acquire extracellular glucose to synthesize the lipids that are subsequently 'burned' for FAO in the mitochondria 35 . IL-7 signals also support the longevity of memory CD8 + T cells by promoting the import of extracellular glycerol, which is used to synthesize the triacylglycerols that are used to fuel FAO 36 . This seems like a rather complicated scheme for the cell, because rather than directly 'burning' extracellular fatty acids, memory T cells synthesize fatty acids for mitochondrial FAO. At present, precisely why FAO is tied to the SRC and enhanced mitochondrial mass of memory T cells is not clear. While less is known about memory CD4 + T cell metabolism, signaling via receptors of the Notch family regulates glucose uptake in these cells, which is critical for their survival 37 . How this glucose uptake relates to FAO, and whether memory CD4 + T cells and memory CD8 + T cells have distinct metabolic machinery to support longevity, remains to be determined.
Integrating metabolism in immunotherapy design
The generation of robust, stable populations of antigen-specific T cells is a goal of vaccination and cell-based therapies to prevent and treat various diseases. Targeting metabolic pathways to enhance T cell function and persistence has now come into focus. While the inhibition of mTOR can promote memory T cells 29, 30 , the administration of mTOR inhibitors during cancer has varying effects, promoting effector T cells in one model 38 and inhibiting effector T cells in another 39 . While such varying results are probably caused by dose, timing and/or characteristics of different tumors, it is clear that modulating metabolism in these cells via mTOR has extremely potent effects on T cells. Looking forward, careful consideration of how various treatments alter specific cellular metabolic pathways in disease settings is needed (Fig. 3a) . In addition to therapies aimed at mTOR, therapies aimed at other molecular targets within metabolic pathways related to memory T cell development, such as AMPK and glycogen-synthase kinase, are under development 40 .
also influences their anti-tumor function. In T cells, the aminotransferase BCAT negatively regulates mTOR and glycolysis. CD4 + T cells from BCAT-deficient mice exhibit lower leucine transamination and higher intracellular leucine concentrations than those of wild-type T cells, which leads to mTOR activation and higher rates of glycolysis 21 . FAS also has an important role in T cell effector function. Inhibition of the FAS enzyme ACC1, which converts acetyl-CoA to malonyl-CoA (an important substrate for fatty acid elongation), enhances the differentiation of regulatory T cells and limits development of the T H 1, T H 2 and T H 17 subsets of helper T cells 20 . Although lack of ACC1 in CD8 + T cells does not affect effector T cell development, it does confer a shorter cellular lifespan and limits clonal expansion, which suggests that FAS is crucial for CD8 + T cell survival 22 . Overall, fluctuations in the concentrations of amino acids, as well as those of other nutrients and metabolites in the microenvironment, can considerably alter T cell function (Fig.  2) . More research is needed to determine whether a given metabolic pathway is induced in particular cell types to provide biosynthetic precursors for growth, to fuel OXPHOS for ATP production, to maintain redox balance or for other purposes (Fig. 2) .
Several by-products of metabolism can have negative effects on T cell function. Lactate from aerobic glycolysis dampens the cytolytic function of CD8 + T cells 23 and promotes interleukin 17 (IL-17) production by T H 17 cells 24 . The metabolite kynurenine, generated from indoleamine-2,3-dioxygenase-mediated catabolism of tryptophan, is a potent suppressor of the proliferation and effector function of CD8 + T cells 25, 26 and is an inducer of the generation of regulatory T cells via a mechanism dependent on the transcription factor AhR 27, 28 . Thus, the decreased availability of certain amino acids and the accumulation of metabolic waste products act in concert to alter the microenvironment and influence T cell function (Fig. 2) . Questions in this area remain, and current research is focused on understanding how changes in available nutrients and metabolites in particular niches regulate immune-cell differentiation and function.
Memory T cell metabolism
A successful immune response relies on the ability of T cells not only to proliferate extensively and attain effector functions but also to form long-lived memory T cells that can respond again to future antigen encounter. There is intense interest in understanding how long-lived cellular immunity is generated. The metabolic pathways that contribute to the generation of memory T cells following acute infection are now beginning to be defined.
FAO engagement is critical for the generation of memory T cells 29 , while mTOR signals dampen the development of memory T cells 30 . These observations suggest that metabolic reprogramming in T cell populations after the induction of an immune response regulates the stable development of long-lived memory T cells. Underlying their capacity for FAO, memory T cells maintain substantial mitochondrial spare respiratory capacity (SRC) and have greater mitochondrial mass than that of naive or activated T cells 31 . AMPK-a1 signals, which promote FAO, also support the development of memory CD8 + T cells 29, 32 . These phenotypic attributes provide a metabolic advantage to these cells, equipping them for long-term survival and the ability to rapidly recall upon antigen challenge 33 . In support of the idea that the 'metabolic signature' of memory T cells, such as enhanced SRC and mitochondrial mass, underlies their functional and phenotypic characteristics, both of these parameters increase further in memory T cells that form after subsequent rounds of challenge infection. These so-called 'secondary' and 'tertiary' memory T cells are known to persist in even greater numbers than memory T cells that have formed after a single prime-boost and have a marked capacity to rapidly recall 34 . diminishes T H 17 cell-mediated inflammation in models of inflammatory bowel disease and experimental autoimmune encephalomyelitis by selectively limiting the survival and proliferation of T H 17 cells 45 ( Fig. 3a) . Blocking the amino acid transporter Slc7a5, which is important for the differentiation and function of T H 1 and T H 17 cells, with compounds such as JPH203 and BCH also constrains inflammatory T cells 38, 46 . Results such as these suggest that pharmacological blockade of immune-cell metabolism to abrogate inflammation might be a therapeutic possibility in a variety of disease settings.
Broader understanding of the factors that control long-lived and stable T cell function is needed for the improvement of T cell-based vaccination. Adoptive T cell immunotherapy (ACI) is an approach in which T cells from a patient undergo population expansion in vitro and then are transferred back into the patient with the goal of improving their immune response to cancer or chronic viral infection 47 (Fig. 3b) . Cells generated for ACI are expected to maintain their proliferative ability and effector function so that they sufficiently clear tumors or pathogens and are also are expected to form stable memory T cells that can respond again in the future, should the cancer or infection recur. Although it is now known that in order to be effective, immune cells must undergo the correct metabolic reprogramming, relatively little research has focused on manipulating T cell metabolism to enhance vaccination or promote cell longevity after ACI. Exaggerated glycolysis in T cells can accelerate terminal differentiation, while inhibition of glycolysis leads to more stable CD8 + T cell memory development. Studies have shown that limiting glycolysis and promoting mitochondrial metabolism during priming allows more cells to enter the memory T cell pool, and these resulting cells maintain superior antitumor function and persistence after challenge 48, 49 . Because IL-2 strongly promotes glycolysis in T cells, culturing human cells destined for ACI in IL-2 might force their terminal differentiation. Furthermore, upon adoptive transfer, cells that are heavily relying on glycolysis will suffer nutrient deprivation when they enter the host, and as a result, the vast majority will die because they cannot meet their energetic demands. Instead, providing signals that promote mitochondrial metabolism, such as those that could be achieved with IL-15 or IL-7, might better equip the cells metabolically for longevity in vivo (Fig. 3a,b) . Given studies showing that tumors and T cells compete for glucose 16, 17 , the timing of when activated T cells will enter a tumor microenvironment, and if nutrient availability to the T cells could be optimized before that time, should be carefully considered 2 (Fig. 3a) . Perhaps the use of inhibitors of glycolysis before the induction of an immune response would allow newly activated immune cells to enter a tumor environment that is more nutrient replete. Although blocking glycolysis generally would presumably inhibit T cell glycolysis, it might not matter if this treatment were administered in a step-wise fashion. In addition, strategies that transiently effect the depletion of inhibitory immune cells, such as regulatory T cells, before the introduction of agents that reinvigorate the immune response, might also allow newly primed effector T cells to enter a more nutrient-rich microenvironment 50 . Aside from creating new therapies, simply incorporating these ideas into current therapeutic strategies might yield much better results for patients (Fig. 3a,b) .
Future outlook
Every biological process is supported by intracellular metabolism. Metabolic pathways provide a common thread that links gene regulation, signaling, function, lifespan and fitness. Integrating information from high-throughput technologies that are now available in metabolomics with proteomics, transcriptomics and epigenetics might yield new information on how to manipulate metabolism to alter other diverse cellular processes. Armed with new information and a comprehensive understanding of how metabolism dictates immune cell Continued investigation into the underlying metabolic features of these cells may reveal new therapeutic targets.
Antibody blockade of inhibitory receptors is another way of targeting metabolism to regulate T cell function. For example, T cells that receive signals via the T cell-inhibitory receptor PD-1 undergo diminished glycolysis and enhanced FAO, which dampens their effector function while promoting longevity 41 . Such results might explain the longevity of T cells observed in some patients with chronic infections or cancer and suggest that PD-1-blocking antibodies might reinvigorate T cell glycolysis, and hence T cell function, in these patients (Figs. 2 and 3a) . Although therapeutic compounds or antibodies that systemically target metabolic processes hold promise, the potential for off-target effects might also be high. Strategies for delivering drugs to specific cell types are needed. Some approaches, such as transporter-mediated drug uptake 42 , bi-specific antibodies 43 and nanoparticle-mediated delivery 44 , require further evaluation.
While a lot of research has focused on the influence of metabolic signals during the generation of T cell responses, metabolic signals can also influence the phenotype of a lineage-committed T cell. Several studies have attempted to manipulate T cell metabolism to skew cell function. For example, dichloroacetate, an inhibitor of the kinase PDK1, fate, researchers might discover novel therapeutic strategies for the treatment of disease.
